Key Takeaways:

• The South Korea–based regenerative medicine company is strengthening its localization strategy across North America.
• The deal will support the demand for Rejuran Cosmetics driven in part by its Sephora launch and expanding Amazon channel.
• The company has supplied the US market with products manufactured in Korea.

The South Korea–based regenerative medicine company strengthens localization strategy across North America.

WHO: Based in California, CG USA is a cosmetics OEM and ODM manufacturer with capabilities across product planning, formula development, manufacturing, filling, packaging, and quality control. The company holds a cosmetics manufacturing license and operates an FDA-registered facility with a quality management system aligned with current good manufacturing practice, or cGMP, standards. Its manufacturing infrastructure also supports production of over-the-counter (OTC) products.

PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. Its diverse portfolio includes medicines, medical devices, cosmetics, and health supplements, all leveraging the core ingredients—DOT PDRN and DOT PN—which are protected by multiple patents. PharmaResearch is headquartered in Gangneung-si, Gangwon-do, South Korea, and has a US subsidiary in Costa Mesa, California.

Rejuran Cosmetics is PharmaResearch's premium dermacosmetics brand, developed from the company's regenerative medicine technology. Built around DOT c-PDRN, the company's patented cosmetic-grade PDRN ingredient, the brand has expanded its US presence through online and offline retail channels, including Sephora and...